Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceProductive …Markets InsiderCAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, … Continue reading
Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceGuruFocus.comCAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced … Continue reading
Gizmodo |
The FDA Just Approved Another Promising Immunotherapy for Cancer
Gizmodo The FDA’s approval of Yescarta, manufactured by Kite Pharma, comes just a few months after its first approval—an indication of just how quickly the field of immunotherapy is moving. Several other companies also have CAR-T therapies in the works. Cutting-edge immunotherapy treatment approved for another deadly cancerWashington Post Gilead cancer immunotherapy wins US approval with $373000 priceNasdaq F.D.A. Approves Second Gene-Altering Treatment for Cancer – The …New York Times PR Newswire (press release) –Markets Insider –The San Diego Union-Tribune –FDA.gov all 106 news articles » |